Cargando…

Expression and therapeutic significance of estrogen receptor β in malignant pleural mesothelioma

Detalles Bibliográficos
Autores principales:	Pinton, Giulia, Moro, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481858/ https://www.ncbi.nlm.nih.gov/pubmed/28670467 http://dx.doi.org/10.4155/fsoa-2017-0007

Ejemplares similares

Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
por: Pinton, Giulia, et al.
Publicado: (2014)

Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells
por: Manente, Arcangela G., et al.
Publicado: (2015)

Estrogen Receptor β Exerts Tumor Repressive Functions in Human Malignant Pleural Mesothelioma via EGFR Inactivation and Affects Response to Gefitinib
por: Pinton, Giulia, et al.
Publicado: (2010)

Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
por: Al Khatib, MHD Ouis, et al.
Publicado: (2023)

SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells
por: Pinton, Giulia, et al.
Publicado: (2016)

An appropriate choice for immunotherapy in malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2020)

Expression and clinical implications of estrogen receptors in thoracic malignancies: a narrative review
por: Pinton, Giulia, et al.
Publicado: (2021)

Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma
por: Pinton, Giulia, et al.
Publicado: (2012)

Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
por: Moro, Jacopo, et al.
Publicado: (2022)

Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia
por: Zonca, Sara, et al.
Publicado: (2017)

Refining classification of malignant pleural mesothelioma reveals its Achilles’ heel
por: Pateras, Ioannis S.
Publicado: (2019)

Targeting estrogen receptor beta (ERβ) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ERβ expression and functionality
por: Pinton, Giulia, et al.
Publicado: (2018)

Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo
por: Manente, A G, et al.
Publicado: (2013)

Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines
por: Gabano, Elisabetta, et al.
Publicado: (2021)

Clinical significance of histologic subtyping of malignant pleural mesothelioma
por: Brcic, Luka, et al.
Publicado: (2020)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Circulating biomarkers in malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020)

Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice
por: Offin, Michael, et al.
Publicado: (2022)

Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma
por: Fujimoto, Nobukazu, et al.
Publicado: (2014)

The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma
por: Oguh-Olayinka, Lily, et al.
Publicado: (2019)

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma
por: Zauderer, Marjorie G.
Publicado: (2021)

An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma
por: Davis, Alexander, et al.
Publicado: (2022)

CD7 Expression in Malignant Pleural Mesothelioma
por: Hibi, Shigeyoshi, et al.
Publicado: (1992)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
por: Pinton, Giulia, et al.
Publicado: (2013)

Identification of Overexpressed Genes in Malignant Pleural Mesothelioma
por: Morani, Federica, et al.
Publicado: (2021)

Gli as a Novel Therapeutic Target in Malignant Pleural Mesothelioma
por: Li, Hui, et al.
Publicado: (2013)

Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma
por: Lapidot, Moshe, et al.
Publicado: (2022)

An exception that proves the rule: recurrence free survival five years after extrapleural pneumonectomy for malignant pleural mesothelioma
por: Treasure, Tom, et al.
Publicado: (2014)

Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
por: Meirson, Tomer, et al.
Publicado: (2022)

KRAS signaling in malignant pleural mesothelioma
por: Marazioti, Antonia, et al.
Publicado: (2021)

AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma
por: Zito Marino, Federica, et al.
Publicado: (2022)

Metabolic rewiring and redox alterations in malignant pleural mesothelioma
por: Urso, Loredana, et al.
Publicado: (2019)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_airiov9cta7d44pn1pnen6u9co